A Phase 1b, Open-Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety , Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination with the PARP Inhibitor BGB-290 in Subjects with Advanced Solid Tumors
- Markman, Ben (Primary Chief Investigator (PCI))
- Frentzas, Sophia (Primary Chief Investigator (PCI))
Project: Research